Revance Therapeutics, Inc. (NASDAQ:RVNC) Receives Average Rating of “Hold” from Analysts

Revance Therapeutics, Inc. (NASDAQ:RVNC) has been given a consensus rating of “Hold” by the nine analysts that are presently covering the stock, Marketbeat reports. Eight analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $8.39.

RVNC has been the subject of a number of analyst reports. HC Wainwright restated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Needham & Company LLC restated a “hold” rating on shares of Revance Therapeutics in a research report on Friday, January 17th. Barclays decreased their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. StockNews.com began coverage on Revance Therapeutics in a research note on Friday, February 14th. They set a “hold” rating for the company. Finally, Mizuho lowered their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th.

Institutional Investors Weigh In On Revance Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. LMR Partners LLP bought a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $11,648,000. Alpine Associates Management Inc. acquired a new position in Revance Therapeutics during the 3rd quarter worth $21,605,000. Oddo BHF Asset Management Sas bought a new position in Revance Therapeutics in the 3rd quarter valued at $3,763,000. FNY Investment Advisers LLC increased its stake in shares of Revance Therapeutics by 160.4% in the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after buying an additional 294,323 shares during the period. Finally, Wellington Management Group LLP bought a new stake in shares of Revance Therapeutics during the third quarter worth $2,315,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Thursday. The company has a 50-day moving average of $3.40 and a 200-day moving average of $4.57. Revance Therapeutics has a 52 week low of $2.30 and a 52 week high of $7.56. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.